Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2433 Neoplasms 1842 Carcinoma, Non-Small-Cell Lung 1609 Prostatic Neoplasms 1312 Colorectal Neoplasms 1144 Lung Neoplasms 991 Neoplasm Metastasis 835 Multiple Myeloma 800 Leukemia, Myeloid, Acute 778 Ovarian Neoplasms 685 Pancreatic Neoplasms 671 Melanoma 667 Squamous Cell Carcinoma of Head and Neck 592 Carcinoma, Hepatocellular 570 Recurrence 568 Brain Neoplasms 528 Glioblastoma 519 Stomach Neoplasms 503 Head and Neck Neoplasms 502 Triple Negative Breast Neoplasms 473 Lymphoma 461 Uterine Cervical Neoplasms 457 Carcinoma, Renal Cell 429 Precursor Cell Lymphoblastic Leukemia-Lymphoma 421 Lymphoma, Non-Hodgkin 390 Endometrial Neoplasms 386 Sarcoma 369 Urinary Bladder Neoplasms 356 Lymphoma, Large B-Cell, Diffuse 356 Lymphoma, Follicular 356

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Anal Cancer Metastatic × 1 year × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡